Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression

K. Morimoto, T. Yamada, N. Furuya, H. Tanaka, A. Yoshimura, T. Oba, M. Hibino, T. Fukuda, Y. Goto, A. Nakao, S. Ogusu, Y. Okazaki, T. Harada, T. Ota, K. Masubuchi, K. Mikami, T. Hata, S. Matsumoto, R. Honda, K. Date, Y. Chihara, K. Takayama

Open source

DOI: 10.1016/j.esmorw.2025.100152
Published: 06
Container: ESMO Real World Data and Digital Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmorw.2025.100152,
  title = {Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression},
  author = {K. Morimoto and T. Yamada and N. Furuya and H. Tanaka and A. Yoshimura and T. Oba and M. Hibino and T. Fukuda and Y. Goto and A. Nakao and S. Ogusu and Y. Okazaki and T. Harada and T. Ota and K. Masubuchi and K. Mikami and T. Hata and S. Matsumoto and R. Honda and K. Date and Y. Chihara and K. Takayama},
  year = {2025},
  journal = {ESMO Real World Data and Digital Oncology},
  doi = {10.1016/j.esmorw.2025.100152},
  url = {https://doi.org/10.1016/j.esmorw.2025.100152}
}

RIS

TY  - JOUR
TI  - Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression
AU  - K. Morimoto
AU  - T. Yamada
AU  - N. Furuya
AU  - H. Tanaka
AU  - A. Yoshimura
AU  - T. Oba
AU  - M. Hibino
AU  - T. Fukuda
AU  - Y. Goto
AU  - A. Nakao
AU  - S. Ogusu
AU  - Y. Okazaki
AU  - T. Harada
AU  - T. Ota
AU  - K. Masubuchi
AU  - K. Mikami
AU  - T. Hata
AU  - S. Matsumoto
AU  - R. Honda
AU  - K. Date
AU  - Y. Chihara
AU  - K. Takayama
PY  - 2025
JO  - ESMO Real World Data and Digital Oncology
DO  - 10.1016/j.esmorw.2025.100152
UR  - https://doi.org/10.1016/j.esmorw.2025.100152
ER  -

APA

Morimoto, K., Yamada, T., Furuya, N., Tanaka, H., Yoshimura, A., Oba, T., Hibino, M., Fukuda, T., Goto, Y., Nakao, A., Ogusu, S., Okazaki, Y., Harada, T., Ota, T., Masubuchi, K., Mikami, K., Hata, T., Matsumoto, S., Honda, R., Date, K., Chihara, Y., & Takayama, K. (2025). Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression. ESMO Real World Data and Digital Oncology. https://doi.org/10.1016/j.esmorw.2025.100152

Source records

doaj · retrieved 2026-09-26T08:43:51.955Z